Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections

被引：4

作者：

Nawar, Tamara ^{[1
]}

Kanafani, Zeina A. ^{[1
]}

机构：

[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Infect Dis, Beirut, Lebanon

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2015年 / 13卷 / 07期

关键词：

complicated skin and skin structure infection; lipoglycopeptide; methicillin-resistant S; aureus; telavancin; vancomycin; SOFT-TISSUE INFECTIONS; IN-VITRO ACTIVITY; STAPHYLOCOCCUS-AUREUS INFECTIONS; VANCOMYCIN-INTERMEDIATE; STANDARD THERAPY; BACTERICIDAL ACTIVITY; PHARMACOKINETICS; LIPOGLYCOPEPTIDE; EFFICACY; SAFETY;

D O I：

10.1586/14787210.2015.1043889

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Methicillin-resistant Staphylococcusaureus has emerged as a major causative pathogen in complicated skin and skin structure infections (cSSSIs). Unfortunately, treatment failure with vancomycin has been increasingly reported. Over the past decade, several alternative antimicrobial agents have been studied and approved for the treatment of cSSSIs. One such agent is the lipoglycopeptide telavancin, which was approved by the US FDA 2009. Given its dual mechanism of action, telavancin is characterized by a highly bactericidal activity and low potential for resistance selection. In addition, in clinical trials, it was efficacious and safe in the treatment of cSSSI. The purpose of this review is to give a background overview of telavancin, highlighting its microbiological, pharmacokinetic and pharmacodynamics characteristics, to summarize the available evidence for its use in the treatment of cSSSIs, and to provide an updated evaluation of its safety profile.

引用

页码：825 / 833

页数：9

共 61 条

[11] Single-Dose Pharmacokinetics and Tolerability of Telavancin in Elderly Men and Women [J].

Goldberg, Michael R. ;

Wong, Shekman L. ;

Shaw, Jeng-Pyng ;

Kitt, Michael M. ;

Barriere, Steven L. .

PHARMACOTHERAPY, 2010, 30 (08) :806-811

[12] Lack of Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Telavancin [J].

Goldberg, Michael R. ;

Wong, Shekman L. ;

Shaw, Jeng-Pyng ;

Kitt, Michael M. ;

Barriere, Steven L. .

PHARMACOTHERAPY, 2010, 30 (01) :35-42

[13]

GRIFFITH RS, 1981, REV INFECT DIS, V3, pS200

[14] High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections -: Efficacy and toxicity [J].

Hidayat, Levita K. ;

Hsu, Donald I. ;

Quist, Ryan ;

Shriner, Kimberly A. ;

Wong-Beringer, Annie .

ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (19) :2138-2144

[15] Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus [J].

Higgins, DL ;

Chang, R ;

Debabov, DV ;

Leung, J ;

Wu, T ;

Krause, KA ;

Sandvik, E ;

Hubbard, JM ;

Kaniga, K ;

Schmidt, DE ;

Gao, QF ;

Cass, RT ;

Karr, DE ;

Benton, BM ;

Humphrey, PP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :1127-1134

[16]

Kanafani Zeina A, 2006, Expert Rev Anti Infect Ther, V4, P743, DOI 10.1586/14787210.4.5.743

[17] Tedizolid (TR-701): a new oxazolidinone with enhanced potency [J].

Kanafani, Zeina A. ;

Corey, G. Ralph .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (04) :515-522

[18] Ceftaroline fosamil: drug profile and clinical data [J].

Kanafani, Zeina A. .

FUTURE MICROBIOLOGY, 2011, 6 (01) :9-18

[19] Bacterial skin and soft tissue infections in adults: A review of their epidemiology, pathogenesis, diagnosis, treatment and site of care [J].

Ki, Vincent ;

Rotstein, Coleman .

CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2008, 19 (02) :173-184

[20] Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review [J].

Kmeid, Joumana ;

Kanafani, Zeina A. .

CORE EVIDENCE, 2015, 10 :39-47

← 1 2 3 4 5 6 7 →